click on circles to display study description...
abemaciclib plus endocrine therapy (n=2808) vs. endocrine therapy (n=2829)
randomized controlled trial
abemaciclib plus endocrine therapy
abemaciclib: 150mg 2/day
endocrine therapy
breast cancer - adjuvant
Exclusion criteria: Patients with occult breast cancer, metastatic disease, or node-negative breast cancer, and, after a protocol amendment, patients with inflammatory breast cancer, who received treatment with ET for breast cancer prevention, raloxifene, and/or a CDK4/6 inhibitor and with venous thromboembolic events
open label
603 sites in 38 countries (worldwide)
P3 / IDFS at 1-sided at 0.025 with 2 IA (1st IA at 0.0015, 2nd IA at 0.0092 and final analysis at 0.0220 all at 1-sided)
Adding abemaciclib to endocrine therapy increased significantly the IDFS in patients with HR-positive, and HER-negative
powered by vis.js Network